{
  "id": "5c588efb86df2b9174000004",
  "type": "factoid",
  "question": "What is the mechanism of action of Brigatinib?",
  "ideal_answer": "Brigatinib targets anaplastic lymphoma kinase. It is used for treatment of lung cancer (NSCLC).",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/29256901",
    "http://www.ncbi.nlm.nih.gov/pubmed/28475456",
    "http://www.ncbi.nlm.nih.gov/pubmed/29119148",
    "http://www.ncbi.nlm.nih.gov/pubmed/30394941",
    "http://www.ncbi.nlm.nih.gov/pubmed/27780853",
    "http://www.ncbi.nlm.nih.gov/pubmed/29403310",
    "http://www.ncbi.nlm.nih.gov/pubmed/28597393",
    "http://www.ncbi.nlm.nih.gov/pubmed/28435288",
    "http://www.ncbi.nlm.nih.gov/pubmed/29935304",
    "http://www.ncbi.nlm.nih.gov/pubmed/30191596",
    "http://www.ncbi.nlm.nih.gov/pubmed/30251885",
    "http://www.ncbi.nlm.nih.gov/pubmed/30253203",
    "http://www.ncbi.nlm.nih.gov/pubmed/29856687",
    "http://www.ncbi.nlm.nih.gov/pubmed/29187012",
    "http://www.ncbi.nlm.nih.gov/pubmed/27144831",
    "http://www.ncbi.nlm.nih.gov/pubmed/29174221",
    "http://www.ncbi.nlm.nih.gov/pubmed/28536155",
    "http://www.ncbi.nlm.nih.gov/pubmed/29032042"
  ],
  "snippets": [
    {
      "text": "Molecular inhibitory mechanism study on the potent inhibitor brigatinib against four crizotinib-resistant ALK mutations.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30191596",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "As a potent and selective drug, brigatinib exhibits high efficacy against wild-type and mutant anaplastic lymphoma kinase (ALK) proteins to treat non-small cell lung cancer. In this work, the mechanisms of brigatinib binding to wild type and four mutant ALKs were investigated to gain insight into the dynamic energetic and structural information with respect to the design of novel inhibitors. Comparison between ALK-brigatinib and ALK-crizotinib suggests that the scaffold of brigatinib is well anchored to the residue Met1199 of hinge region by two hydrogen bonds, and the residue Lys1150 has the strong electrostatic interaction with the dimethylphosphine oxide moiety in brigatinib. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30191596",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": " Together, the detailed explanation of mechanisms of those mutations with brigatinib further provide several guidelines for the development of more effective ALK inhibitors.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30191596",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "PURPOSE OF REVIEW: We describe recent developments in the rapidly evolving field of anaplastic lymphoma kinase-targeting agents.RECENT FINDINGS: Five targeted drugs are currently available in the clinic via regular approval or named patient programs, including crizotinib, ceritinib, alectinib, brigatinib and lorlatinib.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30394941",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": " With the limit of a lower number of treated patients (n\u00a0= 359), brigatinib resulted as the most frequently involved in lung toxicity (7%; n\u00a0= 25).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29174221",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Lung toxicity is a rare albeit potentially severe side effect in NSCLC patients receiving ALK-TKIs, apparently more frequent with brigatinib. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29174221",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Ceritinib and alectinib are approved for metastatic ALK positive NSCLC patients, while brigatinib received granted accelerated approval by the United States Food and Drug Administration. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29187012",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Since the discovery, development and approval of crizotinib in 2011, three second-generation ALK-TKIs, ceritinib, alectinib and brigatinib have been approved by the FDA.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29256901",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "In this work, the mechanisms of brigatinib binding to wild type and four mutant ALKs were investigated to gain insight into the dynamic energetic and structural information with respect to the design of novel inhibitors.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30191596",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Comparison between ALK-brigatinib and ALK-crizotinib suggests that the scaffold of brigatinib is well anchored to the residue Met1199 of hinge region by two hydrogen bonds, and the residue Lys1150 has the strong electrostatic interaction with the dimethylphosphine oxide moiety in brigatinib.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30191596",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "These ALK mutations have significant influences on the flexibility of P-loop region and DFG sequences, but do not impair the hydrogen bonds between brigatinib and the residue Met1199 of hinge region.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30191596",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "As a potent and selective drug, brigatinib exhibits high efficacy against wild-type and mutant anaplastic lymphoma kinase (ALK) proteins to treat non-small cell lung cancer.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30191596",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "This report describes the design and synthesis of a series of 2,4-diarylaminopyrimidine-based potent and selective ALK inhibitors culminating in identification of the investigational clinical candidate brigatinib.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27144831",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Brigatinib displayed low nanomolar IC50s against native ALK and all tested clinically relevant ALK mutants in both enzyme-based biochemical and cell-based viability assays and demonstrated efficacy in multiple ALK+ xenografts in mice, including Karpas-299 (anaplastic large-cell lymphomas [ALCL]) and H3122 (NSCLC).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27144831",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [],
  "exact_answer": "anaplastic lymphoma kinase"
}